CHI Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

CHI Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$3.42M	Buy	+60,000	New	+$3.31M	1.36%	17

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

CHI Advisors's MLTX Position: Q3 2023 in Review

CHI Advisors opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2023: 60,000 shares worth $3.42M. The stake represents 1.36% of the portfolio and ranks #17 among its holdings.

118 funds tracked by Wall St. Rank hold MLTX as of Q3 2023.

CHI Advisors held 60,000 shares of MoonLake Immunotherapeutics worth $3.42M as of Q3 2023.
MoonLake Immunotherapeutics was a new CHI Advisors position in Q3 2023.
MoonLake Immunotherapeutics made up 1.36% of CHI Advisors's portfolio in Q3 2023, its #17 holding.
118 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.